Xponance, Inc. Immuno Gen, Inc. Transaction History

Xponance, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$12.46 - $29.95 $4,086 - $9,823	328 Added 2.32%	14,492 $429,000
Q3 2023 Oct 23, 2023	SELL	$14.09 - $19.87 $1,803 - $2,543	-128 Reduced 0.9%	14,164 $224,000
Q2 2023 Jul 13, 2023	BUY	$3.75 - $20.05 $7,601 - $40,641	2,027 Added 16.53%	14,292 $269,000
Q4 2022 Jan 23, 2023	BUY	$4.55 - $6.31 $841 - $1,167	185 Added 1.53%	12,265 $0
Q3 2022 Oct 24, 2022	BUY	$4.48 - $6.47 $2,177 - $3,144	486 Added 4.19%	12,080 $58,000
Q2 2022 Aug 02, 2022	BUY	$3.15 - $5.76 $4,340 - $7,937	1,378 Added 13.49%	11,594 $52,000
Q1 2022 Apr 20, 2022	BUY	$4.26 - $7.48 $43,520 - $76,415	10,216 New	10,216 $49,000
Q3 2021 Nov 05, 2021	SELL	$5.02 - $6.59 $52,679 - $69,155	-10,494 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$5.79 - $8.6 $60,760 - $90,248	10,494 New	10,494 $69,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

Stay updated on Xponance, Inc. with notifications on news.